The future of genetic testing for drug response

Dialogues in Clinical Neuroscience

Volumn 6, Issue 1, 2004, Pages 27-37

  Morris Rosendahl, Deborah J ^a   Fiebich, Bernd L ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

DNA; Drug response; Genetics; Single nucleotide polymorphism

Indexed keywords

SUXAMETHONIUM;

DIAGNOSTIC TEST; DNA SEQUENCE; DRUG METABOLISM; DRUG TARGETING; GENE IDENTIFICATION; GENE TECHNOLOGY; GENETIC ANALYSIS; GENETIC DISORDER; GENETIC PREDISPOSITION; GENETIC TRAIT; GENETIC VARIABILITY; GENOME; HUMAN; INHERITANCE; PHARMACOGENETICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

EID: 1842615134     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (66)

1. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science. 2001;291:1304-1351.
2. Claverie JM. What if there are only 30 000 human genes? Science. 2001;291:1255-1257.
3. Deloukas P, Matthews LH, Ashurst J, et al. The DNA sequence and comparative analysis of human chromosome 20. Nature. 2001;414:865-871.
4. Dunham I, Shimizu N, Roe BA, et al. The DNA sequence of human chromosome 22. Nature. 1999;402:489-495.
5. Hattori M, Fujiyama A, Taylor TD, et al. The DNA sequence of human chromosome 21. Nature. 2000;405:311-319.
6. Heilig R, Eckenberg R, Petit JL, et al. The DNA sequence and analysis of human chromosome 14. Nature. 2003;421:601-607.
7. Skaletsky ÄH, Kuroda-Kawaguchi T, Minx PJ, et al. The male-specific region of the human Y chromosome is a mosaic of discrete sequence classes. Nature. 2003;423:825-837.
8. Watson JD, Crick FH. Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid. Nature. 1953;171:737-738.
9. The Institute for Genomic Research (TIGR). Available at: http://www.tigr.org. Accessed November 25, 2003.
10. National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, Md. Available at: http://www.ncbi.nlm.nih.gov:80/Genomes/index.html. Accessed November 25, 2003.
11. Nussbaum RL, McInnes RR, Willard HF. Thompson and Thompson Genetics in Medicine. 6th ed. Philadelphia, Pa: WB Saunders Company; 2001.
12. Roses AD. Pharmacogenetics. Hum Mol Genet. 2001;10:2261-2267.
13. Zielenski J, Corey M, Rozmahel R, et al. Detection of a cystic fibrosis modifier locus for meconium ileus on human chromsome 19q13. Nat Genet. 1999;22:128-129.
14. Merryweather-Clarke AT, Cadet E, Bomford A, et al. Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis. Hum Mol Genet. 2003;12:2241-2247.
15. Goate A, Chartier-Harlin MC, Mullan M, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature. 1991;349:704-706.
16. Levy-Lehad E, Wasco W, Poorkaj P, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 1995;269:973-977.
17. Sherrington R, Rogaev EI, Liang Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995;375:754-760.
18. Van Nostrand WE, Wagner SL, Haan J, Bakker E, Roos RA. Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis-Dutch type share a decrease in cerebrospinal fluid levels of amyloid β-protein precursor. Ann Neurol. 1992;32:215-218
19. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991;352:77-79.
20. Jakubiczka S, Nedel S, Werder EA, et al. Mutations of the androgen receptor gene in patients with complete androgen insensitivity. Hum Mutation. 1997;9:57-61.
21. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72:971-983.
22. Cystic Fibrosis Mutation Database. The Hospital for Sick Children, Toronto, Canada. Available at: http://www.genet.sickkids.on.ca. Accessed November 25, 2003.
23. Roessler E, Muenke M. How hedgehog might see holoprosencephaly. Hum Mol Genet. 2003;12:R15-R25.
24. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993;90:1977-1981.
25. Zubenko GS, Hughes HB 3rd, Stiffler JS. Neurobiological correlates of a putative risk allele for Alzheimer's disease on chromosome 12q. Neurology. 1999;52:725-732.
26. Vaxillaire M, Boccio V, Philippi A, et al. A gene for maturity onset diabetes of the young (MODY) maps to chromosome 12q. Nat Genet. 1995;9:418-423.
27. McCarthy MI. Growing evidence for diabetes susceptibility genes from genome scan data. Curr Diabetes Rep. 2003;3:159-167.
28. Raby BA, Silverman EK, Lazarus R, Lange C, Kwiatkowski DJ, Weiss ST. Chromosome 12q harbors multiple genetic loci related to asthma and asthma-related phenotypes. Hum Mol Genet. 2003;12:1973-1979.
29. McCarthy LC, Hosford DA, Riley JH, et al. Single nucleotide polymorphism (SNP) alleles in the insulin receptor (INSR) gene are associated with typical migraine. Genomics. 2001;78:135-149.
30. Enlund F, Samuelsson L, Enerback C, et al. Psoriasis susceptibility locus in chromosome region 3q21 identified in patients from southwest Sweden. Eur J Hum Genet. 1999;7:783-790.
31. Veal CD, Capon F, Allen MH, et al. Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locus. Am J Hum Genet. 2002;71:554-564.
32. Bowcock AM, Barker JN. Genetics of psoriasis: the potential impact on new therapies. J Am Acad Dermatol. 2003;49:S51-S56.
33. Garrod AE. Inborn Factors in Disease: An Essay. New York, NY: Oxford University Press; 1931.
34. Kalow W. Pharmacogenetics - Heredity and the Response to Drugs. Philadelphia, Pa: WB Saunders; 1962.
35. Harris H. Enzyme variants in human populations. Johns Hopkins Med J. 1976;138:245-252.
36. Nebert DW. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet. 1997;60:265-271.
37. Sachse C, Brockmoeller J, Bauer S, Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet. 1997;60:284-295.
38. Kerwin RW, Arranz MJ. Psychopharmacogenetics. In: Mcguffin P, Owen MJ, Gottesman II, eds. In: Psychiatric Genetics and Genomics. Oxford, UK: Oxford University Press; 2002:397-413.
39. Bertilsson L, Dahl ML. Polymorphic drug oxidation. CNS Drugs. 1996;5:200-223.
40. Lin KM, Poland RE, Wan YJ, et al. The evolving science of pharmacogenetics: clinical and ethnic perspectives. Psychopharmacol Bull. 1996;32:205-217.
41. Caraco Y. Genetic determinants of drug responsiveness and drug interactions. Therap Drug Monit. 1998;20:517-524.
42. Kidd RS, Straughn AB, Meyer MC, et al. Pharmokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an indiviual homozygous for the CYP2C9*3 allele. Pharmacogenetics. 1999;9:71-80.
43. Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics. In: Hardman JG, Goodman Gilman A, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996:3-27.
44. Marshall A, Hodgson J. DNA chips: an array of possibilities. Nature Biotechnol. 1998;16:27-31.
45. Pfeifer D, Kaufman M, Fiebich B, Spleiss O. Pharmacogenetic profiling with biochips: an innovative concept to improve the efficiency of clinical trials. Proceedings of the Joint Annual Fall Meeting of the German Society for Biochemistry and Molecular Biology (GBM) and the German Society for Experimental and Clinical Pharmacology and Toxicology. 2002. Available at: http://www.gbm-online.de. Accessed November 25, 2003.
46. Lander ES. The new genomics: global views of biology. Science. 1996;274:536-539.
47. Zhao LP, Aragaki C, Hsu L, Quiaoit E. Mapping of complex traits by single-nucleotide polymorphisms. Am J Hum Genet. 1998;63:225-240.
48. Brookes AJ. The essence of SNPs. Gene. 1999;234:177-186.
49. Botstein D, White RL, Skolnick M, Davis RW. Construction of a genetic linkage map in man using restriction fragment length polymorphisms. Am J Hum Genet. 1980;32:314-331.
50. Southern EM. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J Mol Biol. 1975;98:503-517.
51. Hacia JG. Resequencing and mutational analysis using oligonucleotide microarrays. Nat Genet. 1999;21:42-47.
52. The SNP Consortium Ltd. Single nucleotide polymorphisms for biochemical research. Available at: http://snp.cshl.org. Accessed November 25, 2003.
53. The International SNP Map Working Group. A map of human genome sequence variation containing 1.4 million SNPs. Nature. 2001;409:928-933.
54. Matise TC, Sachidanandam R, Clark AG, et al. A 3. 9-centimorgan-resolution human single-nucleotide polymorphism linkage map and screening set. Am J Hum Genet. 2003;73:271-284.
55. Lai E, Riley J, Purvis I, Roses AD. A 4-Mb high-density single nucleotide polymorphism-based map around human APOE. Genomics. 1998;54:31-38.
56. Martin ER, Lai EH, Gilbert JR, et al. SNPing away at complex diseases: analysis of single nucleotide polymorphisms around APOE in Alzheimer's disease. Am J Hum Genet. 2000;67:383-394.
57. Schwab SG, Knapp M, Mondabon S, et al. Support for association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am J Hum Genet. 2003;72:185-190.
58. Hewett D, Samuelsson L, Polding J, et al. Identification of a psoriasis susceptibility candidate gene by linkage disequilibrium mapping with a localized single nucleotide polymorphism map. Genomics. 2002;79:305-314.
59. Deng HW. Population admixture may appear to mask, change or reverse genetic effects of genes underlying complex traits. Genetics. 2001;159:1319-1323.
60. Tsui LC. The spectrum of cystic fibrosis mutations. Trends Genet. 1992;8:392-398.
61. Lipschutz RJ, Fodor SP, Gingeras TR, Lockhart DJ. High density synthetic oligonucleotide arrays. Nat Genet. 1999;21:20-24.
62. Bowtell DD. Options available-from start to finish-for obtaining expression data by microarray. Nat Genet. 1999;21:25-32.
63. Hacia JG, Fan JB, Ryder O, et al. Determination of ancestral alleles for human single-nucleotide polymorphisms using high-density oligonucleotide arrays. Nat Genet. 1999;22:164-167.
64. Chen J, Iannone MA, Li MS, et al. A microsphere-based assay for multiplexed single-nucleotide polymorphism analysis using single base chain extension. Genome Res. 2000;10:549-557.
65. Roses AD. Pharmacogenetics and the future of drug development and delivery. Lancet. 2000;355:1358-1361.
66. Roses AD. Pharmacogenetics and the practice of medicine. Nature. 2000;405:857-865.